京都府立医科大学 血液内科

業績

当教室関連研究の論文

国内外の多く研究機関との共同研究、ならびに多施設共同研究グループへの参加を積極的に行っています。

2022

Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J. The rationale for the dual targeting therapy for RSK2 and AKT in multiple myeloma. Int J Mol Sci, in print.(創薬センターとの共同研究)

Kobayashi T, Yamamoto K, Kagami Y, Machida R, Miyazaki K, Nakamura S, Kuroda J, Maruyama D, Nagai H. Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial. Jpn J Clin Oncol, in print.(多施設共同研究)

Onishi C, Nishikori M, Yakushijin K, Kurahashi S, Nakazawa H, Takamatsu Y, Hashimoto Y, Tatetsu H, Yuichiro Nawa, Yoshida M, Kobayashi T, Oyake T, Yano S, Oride A, Suzuki R. Lymphoma during pregnancy in Japan: a multicenter retrospective cohort study. Int J Hematol. 115(3), 382-390, 2022 (多施設共同研究)

Murayama K, Kiguchi T, Izutsu K, Kameoka Y, Hidaka M, Kato H, Rai S, Kuroda J, Ishizawa K, Ichikawa S, Ando K, Ogura M, Fukushima K, Terui Y. Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma. Ann Hematol, in print.(多施設共同研究)

Tomida A, Chiyonobu T, Tokuda S, Miyachi M, Murashima K, Hirata M, Nakagawa M, Iehara T, Kuroda J, Takayama K. Pleomorphic rhabdomyosarcoma in a young adult harboring a novel germline MSH2 variant. Hum Genome Var, 8, 8, 2022.(遺伝相談室、がんゲノムセンターとの共同研究)

Fujino T, Maruyama D, Miyagi-Maesima A, Tajima K, Saito Y, Ida H, Hosoba R, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Kuroda J, Izutsu K. The outcome of watchful waiting in patients with previously treated follicular lymphoma. Cancer Med, in print.(国立がん研究センターとの共同研究)

Kitaoji T, Noto Y, Kasai T, Mizuhara K, Okamoto H, Tsukamot T, Kuroda J, Mizuno T. A case of neuroleukemiosis: The usefulness of nerve ultrasound as a diagnostic tool. Muscle Nerve, in print.(脳神経内科との共同研究)

Kaneko H, Shimura K, Yoshida M, Matsumoto Y, Kobayashi T, Uchiyama H, Kuroda J, Taniwaki M. Serum Albumin Levels Strongly Predict Survival Outcome of Elderly Patients with Diffuse Large B- Cell Lymphoma Treated with Rituximab-Combined Chemotherapy. Int J Hematol-Oncol Stem Cell Research, 16, 1-8, 2022.

Muramatsu A, Kobayashi T, Kawaji-Kanayama Y, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida S, Shimazaki C, Mizutani S, Tsukamoto T, Shimura Y, Taniwaki M, Teramukai S, Kuroda J, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma. Leuk Lymphoma, 11, 1-8, 2022.(KOTOSG研究)

Tsukamoto T, Tokuda Y, Nakano M, Tashiro K, Kuroda J. Expression of activated B cell gene signature is predictive of the outcome of follicular lymphoma. Blood Adv, 6, 1932-1936, 2022.(ゲノム医科学との共同研究)

Matsumoto Y, Ayani N, Omichi C, Oya N, Matsuoka T, Kobayashi T, Kuroda J, Narumoto J. Diagnostic error about the cause of cytopenia during increasing psychotropic drugs: two case reports. Asian J Psychiatr, 67; 102952, 2022. (精神科との共同研究)

Kawaji-Kanayama Y, Muramatsu A, Sasaki N, Shimura K, Kiyota M, Fuchida S, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Mizutani S, Nakao M, Kaneko H, Kawata E, Hirakawa K, Takahashi R, Shimazaki C, Uchiyama H, Uoshima N, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study. Int J Hematol, 115, 350-362, 2022.(KOTOSG研究)

Taminishi-Katsuragawa Y, Shimura Y, Inoue Y, Matsumura-Kimoto Y, Tsukamoto T, Mizutani S, Kobayashi T, Takeda-Miyata N, Nishimura A, Takatsuka K, Kuroda J. Gastric myeloid sarcoma mimicking a scirrhous gastric cancer. Intern Med, in print.

2021

Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Uoshima N, Kiguchi T, Mita M, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y, Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Mizumoto C, Takeoka T, Io K, Kondo T, Miura M, Minami Y, Ikezoe T, Imagawa J, Takamori A, Kawaguchi A, Sakamoto J, Kimura S. Very low-dose dasatinib in elderly chronic myeloid leukaemia patients (DAVLEC study): a single-arm, multicentre, phase 2 trial. Lancet Haematol, 8, e902-e911, 2021.(多施設共同研究)

Takahashi T, Suzuki R, Yamamoto G, Nakazawa H, Kurosawa M, Kobayashi T, Okada M, Akasaka T, Kim SW, Fukuda T, Ichinohe T, Atsuta Y, Suzumiya J. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan. Hematol Oncol. 39, 66-74, 2021多施設共同研究)

Nakaya A, Shibayama H, Naklatani E, Shimura Y, Kosugi S, Tanaka H, Fuchida S, Kanda J, Uoshima N, Kaneko H, Imada K, Ohta K, Ito T, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicventer retrospective analysis in Kansai Myeloma Forum. eJHaem, 1-9, 2021. (多施設共同研究)

Okamoto H, Uoshima N, Muramatsu A, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Kawata E, Uchiyama H, Kuroda J, Kyoto Clinical Hematology Study Group investigators* Combination of bone marrow biopsy and flow cytometric analysis: The prognostically relevant central approach for detecting bone marrow invasion in diffuse large B-cell lymphoma. Diagnostics, 11:1724, 2021.(KOTOSG研究)

Nagata H, Kuriyama K, Nishikawa R, Ohshiro M, Yamamoto-Sugitani M, Fujimoto-Hirakawa Y, Matsumoto Y, Iwai T, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Fukuda W, Uchiyama H, Kuroda J. Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder. Ann Hematol, 100, 2849-2850, 2021.

Hosono N, Yokoyama H, Aotsuka N, Ando K, Iida H, Ishikawa T, Usuki K, Onozawa M, Kizaki M, Kubo K, Kuroda J, Kobayashi Y, Shimizu T, Chiba S, Nara M, Hata T, Hidaka M, Fujiwara SI, Maeda Y, Morita Y, Kusano M, Lu Q, Miyawaki S, Berrak E, Hasabou N, Naoe T. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia. Int J Clin Oncol, 26:2131-2141, 2021. (多施設共同研究)

Yamauchi T, Yoshida C, Usuki K, Takada S, Matsumura I, Dobashi N, Miyazaki Y, Miyamoto T, Iida H, Asou N, Kuroda J, Ichikawa S, Komatsu N, Mendes W, Honda H, Okubo S, Kurokawa M, Jiang Q, Wei A, Ishizawa K. Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy. Jpn J Clin Oncol, 51:1372-1382, 2021. (多施設共同研究)

Yamashita T, Takamatsu H, Kawamura K, Sunami K, Hagiwara S, Epid GDC, Itagaki M, MD, Takahashi T, Kondo K, Ikeda T, Watakabe-Inamoto K, Handa H, Imaizumi Y, Kuroda J, Murakami J, Nakamura Y, Nakazawa H, Ozaki S, Ohkura M, Takeuchi M, MD, Nagai H, Hanamura I, Nakao S, Tobinai K, Iida S. A nationwide survey on central nervous system multiple myeloma in Japan: Analysis of prognostic factors that improve survival. Br J Haematol, 195:217-229, 2021. (多施設共同研究)

Izutsu K, Ando K, Nishikori M, Shibayama H, Teshima T, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Hojo S, Nakanishi T, Rai S. Phase 2 Study of Tazemetostat for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma with EZH2 Mutation in Japan. Cancer Sci, 112:3627-3635, 2021. (多施設共同研究)

Kawaji-Kanayama Y, Kobayashi T, Muramatsu A, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida S, Shimazaki C, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Shimura Y, Horiike S, Taniwaki M, Kuroda J, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients. Cancer Reports, e1476, 2021.(KOTOSG研究)

Hosen N, Yoshihara S, Takamatsu H, Ri M, Nagata Y, Kosugi H, Shimomura Y, Hanamura I, Fuji S, Minauchi K, Kuroda J, Suzuki R, Nishimura N, Uoshima N, Nakamae H, Kawano Y, Mizuno I, Gomyo H, Suzuki K, Ozaki S, Nakamura S, Imai Y, Kizaki M, Negoro E, Handa H, Iida S. Expression of activated integrin β7 in multiple myeloma patients. Int J Hematol, 114(1); 3-7, 2021. (多施設共同研究)

Katsuragawa-Taminishi Y, Ide D, Maegawa-Matsui S, Fuchida S, Hatsuse M, Murakami S, Kuroda J, Shimazaki C. Acquired Amegakaryocytic Thrombocytopenic Purpura that Presented as Cyclic Thrombocytopenia Associated with Anti-Phospholipid Antibody Syndrome. Clin Hematol Res, 4(1), 42-46, 2021.

Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, Ishikawa T, Kato K, Suehiro Y, Fukuhara N, Ohmine K, Goto H, Yamamoto K, Kanemura N, Ueda Y, Ishizawa K, Kumagai K, Kawasaki A, Saito T, Hashizume M, Shibayama H. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci, 112(7): 2845-2854, 2021(多施設共同研究)

Okamoto H, Kamitsuji Y, Komori Y, Sasaki N, Tsutsumi Y, Miyashita A, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Uoshima N, Kuroda J. Durable remission of chemotherapy-refractory myeloid sarcoma by azacitidine. Tohoku J Exp Med, 254(2); 101-105, 2021.

Matsumoto Y, Tsukamoto T, Chinen Y, Shimura Y, Sasaki N, Nagoshi H, Sato R, Adachi H, Nakano M, Horiike S, Kuroda J, Taki T, Tashiro K, Taniwaki M. Detection of novel and recurrent conjoined genes in non-Hodgkin B-cell lymphoma. J Clin Exp Hematop, 61(2); 71-77, 2021.

Wakita S, Sakaguchi M, Oh, Kako S, Touya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y、Shono K, Shibusawa M、Tadokoro J、Kayamori K, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Myata M, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv,6(1); 238-247, 2022. (多施設共同研究)

Kawai H, Ando K, Maruyama D, Yamamoto K, Kiyohara E, Terui Y, Fukuhara N, Miyagaki T, Tokura Y, Sakata-Yanagimoto M, Igarashi T, Kuroda J, Fujita J, Uchida T, Ishikawa T, Yonekura K, Kato K, Nakanishi T, Nakai K, Matsunaga R, Tobinai K. Phase 2 study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci, 112(6); 2426-2435, 2021. (多施設共同研究)

Matsumoto M, Suzuki K, Kuroda J, Taniwaki M, Sunami K, Kosugi H, Ando K, Maruyama D, Tobinai K, Kher U, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Iida S. Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients. Int J Hematol, 113(6); 777-784, 2021. (多施設共同研究)

Takakuwa T, Ohta K, Nakatani E, Ito T, Kaneko H, Fuchida S, Shimura Y, Yagi H, Shibayama H, Kanda J, Uchiyama H, Kosugi S, Tanaka H, Kawata E, Uoshima N, Ishikawa J, Shibano M, Karasuno T, Shindo M, Shimizu Y, Imada K, Kanakura Y, Kuroda J, Hino M, Nomura S, Takaori-Kondo A, Shimazaki C, Matsumura I. Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma. Hematol Oncol, 39(3):349-357, 2021(多施設共同研究)

Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida S, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Real-world outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis from Kansai Myeloma Forum. Eur J Haematol, 106: 555-562, 2021(多施設共同研究)

Okamoto H, Uoshima N, Kamitsuji Y, Kawata E, Komori Y, Sasaki N, Tsutsumi Y, Tsukamoto T, Mizutani S, Nannya Y, Kuroda J. Paroxysmal Nocturnal Hemoglobinuria Complicated with Essential Thrombocythemia Harboring Concomitant PIGA, CALR And ASXL1 Mutations. Ann Hematol, 100(8):2113-2115, 2021 (KOTOSG関連報告)

Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Utsumi T, Yoshida I, Imaizumi Y, Tokunaga T, Yoshida S, Masaki Y, Murayama T, Yakushijin Y, Suehiro Y, Nosaka K, Dobashi N, Kuroda J, Takamatsu Y, Maruyama D, Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Nagai H. A randomized phase II/III study of R-CHOP versus CHOP combined with dose-dense rituximab for DLBCL: JCOG0601. Blood Adv, 5: 984-993, 2021.(多施設共同研究)

Yasuda T, Takagi T, Asai J, Katoh N, Kuroda J, Kuwahara Y, Morionaga Y, Konishi E, Uchiyama K, Naito Y, Itoh Y. Mycosis fungoides in a patient with ulcerative colitis on anti-tumor necrosis factor-alpha therapy. Clin J Gastroenterol, 14: 170-175, 2021.(本学消化器内科学との共同研究)

Nishiyama D, Chinen Y, Isa R, Fujibayashi Y, Kuwahara-Ota S, Yamaguchi J, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Ts Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. EWSR1 overexpression is a pro-oncogenic event in multiple myeloma. Int J Hematol, 113: 381-394, 2021.(群馬大学血液内科との共同研究)

Maruyama D, Iida S, Ogawa G, Kusumoto S, Fukuhara S, Fukuhara N, Seo S, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Hangaishi A, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Minauchi K, Ohtsuka E, Hanamura I, Tokunaga T, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Miyamoto K, Watanabe Y, Tobinai K, Tsukasaki K, Nagai H. Randomized phase II study to optimize melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). Br J Haematol, 192: 531-541, 2021.(多施設共同研究)

Kanai R, Miyagawa-Hayashino A, Shishido-Hara Y, Nakamura N, Omatsu I, Morinaga Y, Shimura Y, Kuroda J, Itoh K, Konishi E. Mantle cell lymphoma with EBV-positive Hodgkin and Reed-Sternberg-like cells in a patient after autologous PBSCT: Phenotypically distinct but genetically related tumors. Pathol Int, 71: 96-101, 2021.(本学病院病理部との共同研究)

志村勇司、黒田純也. 多発性骨髄腫における骨髄由来免疫抑制細胞の誘導. 臨床免疫・アレルギー科、印刷中.

黒田純也、志村勇司. 多発性骨髄腫治療の展望 -イサツキシマブの登場を踏まえて-. Progress in Medicine, 印刷中.